GABRA3

Chr XX-linked

gamma-aminobutyric acid type A receptor subunit alpha3

Also known as: EPILX2

GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismX-linkedLOEUF 0.701 OMIM phenotype
Clinical SummaryGABRA3
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.33) despite low pLI — interpret in context.
📋
ClinVar Variants
4 unique Pathogenic / Likely Pathogenic· 52 VUS of 107 total submissions
📖
GeneReview available — GABRA3
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.70LOEUF
pLI 0.039
Z-score 2.40
OE 0.33 (0.170.70)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
2.53Z-score
OE missense 0.49 (0.420.58)
97 obs / 196.8 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.33 (0.170.70)
00.351.4
Missense OE?0.49 (0.420.58)
00.61.4
Synonymous OE?0.90
01.21.6
LoF obs/exp: 5 / 15.0Missense obs/exp: 97 / 196.8Syn Z: 0.68

This gene — mechanism propensity

DN
0.82top 10%
GOF
0.80top 10%
LOF
0.2679th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

107 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic1
VUS52
Likely Benign15
Benign3
3
Pathogenic
1
Likely Pathogenic
52
VUS
15
Likely Benign
3
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
3
0
0
3
Likely Pathogenic
0
1
0
0
1
VUS
3
46
3
0
52
Likely Benign
0
5
4
6
15
Benign
0
0
2
1
3
Total3559774

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

95 pathogenic / likely-pathogenic (of 104) ClinVar copy-number / structural variants overlap GABRA3 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

GABRA3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →